BioAtla Investor Presentation Deck

BA3011 Phase 2, part 1 NSCLC Key Takeaways ● Impressive response in monotherapy NSQ PD-1 failure population Promising durability of response Emerging safety profile continues to be differentiated Preparing for FDA interactions in 1H; while awaiting FDA feedback, evaluating more frequent, dose-intensive regimen similar to sarcoma NSQ PD-1 failure population represents a significant unmet need and commercial opportunity bicatla NSQ = nonsquamous BioAtla| Overview 22

View entire presentation